Intracameral moxifloxacin decreases postop endophthalmitis risk three-fold

This large, multicenter, retrospective study found that intracameral moxifloxacin significantly decreases the risk of endophthalmitis after cataract surgery without causing severe complications.

This is yet more proof that Vigamox at any strength is safe and effective. How can anyone not use it?

The study’s authors evaluated the number of surgeries and endophthalmitis cases during the four years before and after the introduction of intracameral moxifloxacin (Vigamox) at 19 clinics in Japan.

The highest concentration (500 μg/mL) was administered in 14,124 cases. Three institutions used 50 to 100 μg/mL of moxifloxacin; nine institutions administered 100 to 300 μg/mL, and seven administered 500 μg/mL.

Endophthalmitis occurred within a month of surgery in eight of 15,958 cases (one in 1,955) without intracameral moxifloxacin administration, compared to three of 18,794 cases (one in 6,265) with intracameral moxifloxacin administration.

Complications such as toxic anterior segment syndrome (TASS) or severe corneal damage were not reported. Moreover, no institution confirmed drug administration errors.